Growth Hormone Secretagogue Comparison: GHRH vs GHRP vs Ghrelin Mimetics vs MK-677

Comprehensive comparison of all growth hormone secretagogue classes — GHRH analogs (Sermorelin, MOD GRF), GHRPs (GHRP-2, GHRP-6, Ipamorelin, Hexarelin), and oral ghrelin mimetics (MK-677) — covering mechanisms, pulse characteristics, side effects, and ideal research applications.

TL;DR

• GHRH analogs + GHRPs = synergistic GH pulses; best combo: MOD GRF 1-29 + Ipamorelin
• Ipamorelin: cleanest GHRP (no cortisol/prolactin); GHRP-6: most hunger; Hexarelin: strongest GH + most side effects
• MK-677: oral convenience, 24h half-life, non-pulsatile — ideal for GH/IGF-1 elevation without injections
• All GH secretagogues work within the HPG axis — no exogenous GH suppression of natural production

Disclaimer: For educational and research purposes only — not medical advice.

Growth hormone (GH) secretagogues are compounds that stimulate the pituitary to release more of its own GH — as opposed to exogenous synthetic GH (rhGH/Somatropin) which suppresses the pituitary. This fundamental difference makes GH secretagogues more physiologically elegant: they work within the body's existing regulatory system, preserving pulsatility and maintaining feedback mechanisms.

Class Overview

GHRH Analogs (Growth Hormone-Releasing Hormone Analogs)

Mechanism: Bind GHRH receptors on anterior pituitary somatotrophs → increase cAMP → stimulate GH synthesis and secretion

GHRPs (Growth Hormone-Releasing Peptides)

Mechanism: Bind GHS-R1a (ghrelin receptor) on pituitary → activate IP3/DAG/calcium pathway → stimulate GH release

Oral Ghrelin Mimetics

MK-677 (Ibutamoren):

• Non-peptide ghrelin receptor agonist
• Oral bioavailability: ~60-70%
• Half-life: ~24 hours (once-daily dosing)
• Dose: 12.5-25mg/day
• GH effect: Continuous elevation throughout 24h (non-pulsatile)
• IGF-1 elevation: Robust and sustained
• Side effects: Water retention (dose-dependent), increased appetite, fatigue (early), potential prolactin elevation at high doses

Mechanistic Synergy: Why GHRH + GHRP Works

GHRH and GHRPs activate different receptor systems with partially overlapping downstream signaling that converges on the secretion machinery. Key synergy mechanisms:

1. Dual cAMP activation: GHRH increases cAMP via Gs-coupled GHRH receptor; GHRPs activate IP3/DAG/calcium via Gq-coupled GHS-R1a. These parallel pathways each partially activate secretory machinery; together they fully activate it → multiplicative GH release.

2. Somatostatin antagonism: GHRPs reduce somatostatin (GH-inhibitory hormone) release from the hypothalamus, reducing the GH "brake" while GHRH applies the "accelerator." Combined effect is dramatically amplified.

3. Timing synchronization: Both are administered simultaneously; the pituitary receives maximum pro-secretory signaling at exactly the same time.

Result: Combined GH release is typically 3-10x larger than either compound alone at the same dose.

Choosing the Right Secretagogue for Research Goals

Monitoring Response to GH Secretagogues

Key biomarkers to monitor:

• IGF-1: Primary downstream marker; should rise 20-50% with effective protocols; target upper-normal range (200-350 ng/mL)
• Fasting glucose/insulin: GH is an insulin antagonist; monitor for glucose elevation
• Prolactin: Especially important with GHRP-6 and Hexarelin
• Water retention: Clinical observation; track body weight and blood pressure

Frequently Asked Questions

Q: Can GH secretagogues be used indefinitely? A: Unlike exogenous GH which suppresses the pituitary, GH secretagogues work within the physiological regulatory system. However, continuous administration may gradually reduce pituitary sensitivity over months-years. Many researchers cycle — 3-6 months on, 1-2 months off. No long-term human studies have established optimal cycle protocols.

Q: Does taking GH secretagogues increase IGF-1 to concerning levels? A: At research doses (100-300mcg of GHRPs), IGF-1 elevation is typically 20-50% above baseline — often bringing low-normal IGF-1 into a more optimal range. Elevated IGF-1 in the context of pulsatile GH secretion is physiologically different from the sustained supraphysiological IGF-1 from exogenous GH. Monitoring IGF-1 to keep it within the age-appropriate normal range is the standard research approach.

Use the Reconstitution Calculator → /calculators/reconstitution

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions